GW0742
GW0742 is a potent, selective PPAR-delta agonist studied preclinically for metabolic and endurance effects. Closely related to the better-known GW501516, it shifts muscle toward fatty-acid oxidation, and is sold in the research grey market as an endurance and fat-loss agent despite no human data.
01 Overview
GW0742 activates the nuclear receptor PPAR-delta, driving expression of genes that increase fat oxidation, mitochondrial biogenesis and oxidative fibre metabolism in skeletal muscle. In rodents this improves running endurance and metabolic markers, mirroring its sibling GW501516 (cardarine).
It has no clinical development programme and, like other PPAR-delta agonists, carries theoretical carcinogenicity concerns from long-term animal studies of the class. It exists purely as a research compound with anecdotal human use.
02 Mechanism
Selective PPAR-delta agonist that upregulates fatty-acid oxidation, mitochondrial biogenesis and oxidative metabolism in skeletal muscle, shifting fuel use toward fat.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Grey-market (unvalidated) | 5–10 mg/day | Oral | Extrapolated from GW501516 use; no validated protocol |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased fat oxidationShifts substrate use toward fat in muscle in animal models. | Preclinical | ||
| Improved enduranceEnhanced running capacity in rodents via oxidative reprogramming. | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Unknown human safetyNo human trials; safety and dosing undefined. | Moderate | Uncharacterised | Unconfirmed | |
| Theoretical carcinogenicityPPAR-delta agonists caused tumours in long-term rodent studies of the class. | Severe | Class concern | Preclinical |